Antonius T. Otten

Groningen, GR 9713GZ, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Interleukin-23p19 Inhibitors in Inflammatory Bowel Disease: From Current Insights to Future Directions.

Interleukin-23p19 Inhibitors in Inflammatory Bowel Disease: From Current Insights to Future Directions.

Journal: Journal of personalized medicine

Published: December 22, 2025

Interleukin-18 Inhibition in Inflammatory Bowel Disease: A Delicate Balance.

Interleukin-18 Inhibition in Inflammatory Bowel Disease: A Delicate Balance.

Journal: Inflammatory bowel diseases

Published: March 05, 2024

The Future of Therapeutic Drug Monitoring in Inflammatory Bowel Disease: An Emphasis on the Essential Ingredients.

The Future of Therapeutic Drug Monitoring in Inflammatory Bowel Disease: An Emphasis on the Essential Ingredients.

Journal: Inflammatory bowel diseases

Published: July 31, 2023

Effects of ileocolonic delivered vitamin B2, B3 and C (ColoVit) or the Groningen anti-inflammatory diet on disease course and microbiome of patients with Crohn's disease (VITA-GrAID study): a protocol for a randomised and partially blinded trial.

Effects of ileocolonic delivered vitamin B2, B3 and C (ColoVit) or the Groningen anti-inflammatory diet on disease course and microbiome of patients with Crohn's disease (VITA-GrAID study): a protocol for a randomised and partially blinded trial.

Journal: BMJ open

Published: March 14, 2023

Capsules with Ileocolonic-Targeted Release of Vitamin B2, B3, and C (ColoVit) Intended for Optimization of Gut Health: Development and Validation of the Production Process.

Capsules with Ileocolonic-Targeted Release of Vitamin B2, B3, and C (ColoVit) Intended for Optimization of Gut Health: Development and Validation of the Production Process.

Journal: Pharmaceutics

Published: March 11, 2023

Assessment of Fecal Glycosylated Mucins as Novel Biomarkers in Inflammatory Bowel Diseases.

Assessment of Fecal Glycosylated Mucins as Novel Biomarkers in Inflammatory Bowel Diseases.

Journal: Inflammatory bowel diseases

Published: February 10, 2023

Clinical Validation of a Capillary Blood Home-Based Self-Sampling Technique for Monitoring of Infliximab, Vedolizumab, and C-Reactive Protein Concentrations in Patients With Inflammatory Bowel Disease.

Clinical Validation of a Capillary Blood Home-Based Self-Sampling Technique for Monitoring of Infliximab, Vedolizumab, and C-Reactive Protein Concentrations in Patients With Inflammatory Bowel Disease.

Journal: Inflammatory bowel diseases

Published: February 07, 2023

The Risk of Developing Long COVID in Patients With Inflammatory Bowel Diseases: Do Immunosuppressive Drugs Matter?

The Risk of Developing Long COVID in Patients With Inflammatory Bowel Diseases: Do Immunosuppressive Drugs Matter?

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: December 27, 2022

Working towards a comprehensive appraisal of vaccine-induced immunity against SARS-CoV-2 in IBD.

Working towards a comprehensive appraisal of vaccine-induced immunity against SARS-CoV-2 in IBD.

Journal: The lancet. Gastroenterology & hepatology

Published: November 24, 2022

Temporary diverting stoma in therapy-refractory luminal colonic Crohn's disease: an alternative to immediate colorectal resection?

Temporary diverting stoma in therapy-refractory luminal colonic Crohn's disease: an alternative to immediate colorectal resection?

Journal: Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland

Published: July 18, 2022

The effect of riboflavin supplementation on the systemic redox status in healthy volunteers: A post-hoc analysis of the RIBOGUT trial.

The effect of riboflavin supplementation on the systemic redox status in healthy volunteers: A post-hoc analysis of the RIBOGUT trial.

Journal: Free radical biology & medicine

Published: June 21, 2022

Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease.

Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease.

Journal: Frontiers in immunology

Published: April 14, 2022

Showing 1-12 of 19

Last Updated: 09/26/2026